Navigating adalimumab biosimilars: an expert opinion

The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars - (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma - for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyrimoz...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Vered Abitbol (Autor), Salim Benkhalifa (Autor), Caroline Habauzit (Autor), Hubert Marotte (Autor)
Format: Knjiga
Izdano: Becaris Publishing Limited, 2023-10-01T00:00:00Z.
Teme:
Online pristup:Connect to this object online.
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

Connect to this object online.

3rd Floor Main Library

Detalji primjeraka od 3rd Floor Main Library
Signatura: A1234.567
Primjerak 1 Dostupno